ARS Pharmaceuticals
SPRY
SPRY
201 hedge funds and large institutions have $751M invested in ARS Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 60 increasing their positions, 56 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
3.97% more ownership
Funds ownership: 90.01% → 93.99% (+4%)
7% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 56
28% less capital invested
Capital invested by funds: $1.04B → $751M (-$285M)
Holders
201
Holding in Top 10
3
Calls
$2.1M
Puts
$532K
Top Buyers
| 1 | +$27M | |
| 2 | +$17.3M | |
| 3 | +$9.51M | |
| 4 |
TCM
Tyro Capital Management
Miami,
Florida
|
+$9.33M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.05M |
Top Sellers
| 1 | -$18.6M | |
| 2 | -$17.5M | |
| 3 | -$7.5M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.88M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
-$4.62M |
